Softwr

Healthcare · head to head

Annalise.ai vs Gleamer

Annalise.ai logo

Annalise.ai

Healthcare

Multi-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model

From
On request
Rated
-
Full reviewWebsite
Gleamer logo

Gleamer

Healthcare

CE marked and FDA cleared imaging AI suite for bone trauma and chest, now owned by RadNet

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Annalise.ai the United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.; Gleamer radNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • They diverge on capability: Annalise.ai covers Annalise Enterprise CXR, Gleamer covers BoneView.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Annalise.ai and Gleamer actually diverge.

Attributes where Annalise.ai and Gleamer differ
AttributeAnnalise.aiGleamer

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web, Cloud, On-premise), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Annalise.ai

  • Annalise Enterprise CXR
  • Annalise Enterprise CTB
  • Triage and notification
  • Worklist reprioritisation
  • Localisation overlays
  • Confidence output
  • PACS-native deployment
  • On-premise or cloud inference

Only in Gleamer

  • BoneView
  • ChestView
  • BoneAge
  • BoneMetrics
  • LungCT and BoneCT
  • BreastView
  • Pixyl.Neuro
  • Gleamer Copilot

What people use each for

The jobs each tool is most often brought in to do.

Annalise.ai

  • An emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnestnot Gleamer
  • A teleradiology provider covering many small hospitals that needs consistent triage before a human readsnot Gleamer
  • A screening programme in Europe where the broader CE marked decision support indication, rather than the narrow United States triage clearance, is what is being deployednot Gleamer
  • A radiology department building an AI governance programme that wants one vendor covering both chest radiograph and head CT rather than contracting two separate algorithm suppliersnot Gleamer

Gleamer

  • An emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident themenot Annalise.ai
  • An urgent care network standardising musculoskeletal reading quality across sites with variable radiology covernot Annalise.ai
  • A paediatric service automating bone age assessment to remove a slow manual atlas comparisonnot Annalise.ai
  • An orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstationnot Annalise.ai

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Annalise.ai

  • The United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.
  • Triage AI reprioritises a worklist but does not change clinical decisions on its own, so departments that do not redesign how urgent studies are picked up see no measurable improvement in time to treatment.
  • Published validation is largely reader study evidence on detection of individual findings; prospective evidence of shorter time to treatment in routine emergency care is thin.
  • The Annalise brand is being migrated under the Harrison.ai name for the critical care offering, which creates ambiguity in multi-year contracts about what product name is actually being supported.
  • A high finding count raises the alert burden, and departments report that low prevalence findings generate false positives that erode radiologist trust unless the alerting thresholds are tuned locally.

Gleamer

  • RadNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • The measured benefit is largest for less experienced readers, so a specialist musculoskeletal service will see far less improvement than the published reader studies suggest.
  • Cleared indications differ per module and per market, and the FDA cleared set is narrower than the CE marked European set, so an American buyer cannot rely on European reference sites.
  • Each additional module adds alert volume into the same worklist, and departments running several Gleamer algorithms report needing local threshold tuning to keep radiologist trust.
  • Pricing is per exam and not published, which makes budgeting difficult for an emergency department whose plain film volume swings seasonally.

Pricing, plan by plan

Annalise.ai

On request
  • Annalise Enterprise$undefined/year
    • Priced per study analysed or as an annual volume subscription
    • CXR and CTB licensed separately
    • Cleared finding set differs by market, which changes what you are buying

Gleamer

On request
  • Gleamer Copilot$undefined/year
    • Priced per exam analysed or as an annual volume subscription
    • Modules licensed individually or bundled as Copilot
    • Cleared and CE marked indication differs per module and per market

Which should you pick?

Choose Annalise.ai if

  • You need annalise enterprise cxr.
  • You work on Web, Cloud, On-premise.
  • You also want annalise enterprise ctb.
Annalise.ai review

Choose Gleamer if

  • You need boneview.
  • You work on Web, Cloud, On-premise.
  • You also want chestview.
Gleamer review

Questions people ask

Is Annalise.ai or Gleamer better?
Neither clearly leads. Annalise.ai starts at On request and Gleamer at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Annalise.ai or Gleamer?
Annalise.ai starts at On request and Gleamer at On request.
Does Annalise.ai or Gleamer run on more platforms?
Both run on Web, Cloud, On-premise, so platform support will not decide this one for you.
What is Annalise.ai best used for?
Annalise.ai is most often used for an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest, a teleradiology provider covering many small hospitals that needs consistent triage before a human reads, a screening programme in europe where the broader ce marked decision support indication, rather than the narrow united states triage clearance, is what is being deployed, a radiology department building an ai governance programme that wants one vendor covering both chest radiograph and head ct rather than contracting two separate algorithm suppliers. Of those, an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest and a teleradiology provider covering many small hospitals that needs consistent triage before a human reads are not what Gleamer is typically brought in for.
What can Annalise.ai do that Gleamer cannot?
Annalise.ai covers Annalise Enterprise CXR, Annalise Enterprise CTB, Triage and notification, Worklist reprioritisation. Gleamer covers BoneView, ChestView, BoneAge, BoneMetrics.

Answered from the vendors’ own pages

Annalise.ai: How many findings are FDA cleared?

Around ten across chest X-ray and head CT, for triage and notification only. The model reports far more findings than that; the rest are not cleared in the United States.

Gleamer: Who owns Gleamer?

RadNet agreed to acquire Gleamer in February 2026 for around two hundred and fifteen million euros upfront. RadNet also owns DeepHealth, a competing AI portfolio.

Annalise.ai: Is the European position different?

Yes. CE marking under the medical device regulation covers a broader decision support indication than the United States triage and notification clearances, so the same software is a different regulatory product depending on where you deploy it.

Gleamer: Is BoneView FDA cleared?

Yes, BoneView holds 510(k) clearance including for paediatric fracture detection, but the cleared finding set is narrower than the CE marked indication in Europe.

Annalise.ai: Does it diagnose?

No. In the United States it is a triage and notification device: it flags studies for earlier review, and the radiologist makes the diagnosis.

Gleamer: What does the evidence actually show?

Multi-reader studies reported improved reader sensitivity for fracture detection and fewer false negatives, with the gain concentrated among less experienced readers in emergency settings.

Annalise.ai: Is Annalise.ai becoming Harrison.ai?

The critical care offering is now marketed under the Harrison.ai name. Ask the vendor to name the contracted product explicitly before signing a multi-year deal.

Gleamer: Can I buy just BoneView?

Yes, modules are licensed individually, though the commercial pitch is now the Copilot bundle across modalities.

Share

Related pages

More on Annalise.ai

More on Gleamer

Keep looking

Other head to heads